Project Grant R21CA286523
Award Date
1/1/25
Completion Date
12/31/26
Dollars Obligated
$211K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
College Station, TX, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $419,080 to Virginia Polytechnic Institute & State University (Virginia Tech) to evaluate a combination therapy approach using histotripsy tumor ablation and the immunostimulant N-dihydrogalactochitosan (GC) for treating osteosarcoma. The research aims to characterize the immune responses and effects on metastasis in a murine model, as well as evaluate the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $131,910 to Virginia Polytechnic Institute & State University (Virginia Tech) to investigate treatment strategies and clinical outcomes of histotripsy, a non-thermal ablation technique, for complete ablation of osteosarcoma in canine models. The key objectives are to: 1) investigate the treatment parameters and strategies needed for complete ablation of ex vivo canine...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $514,405 to Sanford Research to investigate the role of cancer-dependent skeletal genes and pathways in the pathogenesis of osteosarcoma. The award will fund research to understand how cancer-dependent pathways involving p53 and Notch regulate premalignant osteoblasts and the development of osteosarcoma, a fatal bone tumor primarily affecting children. The project will utilize genetically...
Oregon State University will receive $500,000 from the National Science Foundation under the Technology, Innovation, and Partnerships program to develop cancer therapeutics for dogs. Specifically, the university will construct and test prototype dual epitope-binding therapeutic antibodies targeting the canine PD-1 protein for the treatment of canine cancers. Researchers will design various single domain antibody configurations and select an optimal construct using recombinant DNA methods and...
This Project Grant award of $452,549, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Emory University and its sub-awardee Baylor College of Medicine to comprehensively characterize and genetically perturb the molecular features of MYC-amplified osteosarcoma (OS), a high-risk subgroup with poor prognosis. The research aims to define the intrinsic and extrinsic tumor microenvironment dynamics driven by the MYC oncogene, and develop novel...
The Department of the Army Medical Command awarded a $1,750,524 project grant to Dana-Farber Cancer Institute, Inc. for research on treatment options for metastatic osteosarcoma. The grant was awarded on August 1, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research through July 31, 2025. The Military Medical Research and Development program aims to transform health care for service members and the public through innovative biomedical research....
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $540,090 to The Regents of the University of California, San Francisco to conduct epigenetic analysis of osteosarcoma (a type of bone cancer) to define subtypes relevant to chemoresistance and metastasis. The overarching goal is to characterize the biological basis for these osteosarcoma subtypes and identify subtype-specific vulnerabilities that could lead to new targeted...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to improve mucosal melanoma therapy by harnessing the immunogenicity of the R3LCMV virus. The $667,553 award to Northwestern University, spanning 2025-2029, has two key objectives: Determine whether neoadjuvant R3LCMV treatment improves disease-free survival in dogs with naturally occurring mucosal melanoma through a placebo-controlled veterinary...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $216,460.00 to Case Western Reserve University to conduct research on epigenetic drivers of lung metastasis in osteosarcoma. The research aims to study key transcription factors and their role in activating genes necessary for metastasis, as well as the interplay between these factors and the lung microenvironment during the metastatic process. The goal is to expand treatment options for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013 to Sanford Research, a non-profit biomedical research organization, to develop the first genetically engineered mouse models that accurately replicate key features of human high-risk rhabdomyosarcoma. The goal is to use these advanced preclinical models to explore the role of the NOTCH1 signaling pathway as both a driver and potential therapeutic target for this aggressive form...